From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
Number of patients (%)
DD/DI arm (N = 86)
HDI arm(N = 80)
Completed therapy
54
(63)
32
(40)
Reasons for discontinuation
Toxicity
11
(13)
14
(17)
Refusal
15
(19)
Disease Progression
10
(12)
19
(24)